Turkey's myelofibrosis treatment patterns revealed in new study
NCT ID NCT07357441
First seen Jan 24, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This study looked back at the medical records of 355 people with myelofibrosis in Turkey who were treated with the drug ruxolitinib for at least 3 months. The goal was to understand patient characteristics, treatment patterns, and side effects in everyday medical practice. No new treatments were given; researchers simply collected existing data to see how the disease is managed in the real world.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.